EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC

Cancer Genet. 2024 Jan:280-281:13-16. doi: 10.1016/j.cancergen.2023.12.001. Epub 2023 Dec 10.

¹ Department of Thoracic Oncology, Aichi Cancer Center Hospital, Japan.
² Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Japan; Division of Translational Oncoimmunology, Aichi Cancer Research Institute, Nagoya, Japan. Electronic address: [email protected].
³ Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Japan.
⁴ Department of Respiratory Surgery, Aichi Cancer Center Hospital, Nagoya, Japan; Department of Thoracic Surgery, Teikyo University Mizonokuchi Hospital, Tokyo, Japan; Division of Translational Oncoimmunology, Aichi Cancer Research Institute, Nagoya, Japan.
⁵ Division of Translational Oncoimmunology, Aichi Cancer Research Institute, Nagoya, Japan.
⁶ Department of Thoracic Oncology, Aichi Cancer Center Hospital, Japan; Division of Translational Oncoimmunology, Aichi Cancer Research Institute, Nagoya, Japan.

No abstract available

Keywords: ALK rearrangement; Drug resistance; Non-small cell lung cancer; Osimertinib.

Publication types